Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

Hidenori Takahashi, Shigetaka Shimodaira, Masahiro Ogasawara, Shuichi Ota, Masanori Kobayashi, Hirofumi Abe, Yuji Morita, Kazuhiro Nagai, Shunichi Tsujitani, Masato Okamoto, Yukio Suzuki, Yoichi Nakanishi, Yoshikazu Yonemitsu, the DC Vaccine Study Group at the Japanese Society of Immunotherapy for the DC Vaccine Study Group at the Japanese Society of Immunotherapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers. Methods: Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks. Results: The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014). Conclusions: This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.

Original languageEnglish
Pages (from-to)1099-1111
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume65
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis'. Together they form a unique fingerprint.

  • Cite this

    Takahashi, H., Shimodaira, S., Ogasawara, M., Ota, S., Kobayashi, M., Abe, H., Morita, Y., Nagai, K., Tsujitani, S., Okamoto, M., Suzuki, Y., Nakanishi, Y., Yonemitsu, Y., & for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, T. DC. V. S. G. A. T. J. S. O. I. (2016). Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunology, Immunotherapy, 65(9), 1099-1111. https://doi.org/10.1007/s00262-016-1872-z